Browse CNGB3

Summary
SymbolCNGB3
Namecyclic nucleotide gated channel beta 3
Aliases ACHM3; ACHM1; RMCH; achromatopsia (rod monochromacy) 3; achromatopsia (rod monochromacy) 1; CNG channel beta ......
Chromosomal Location8q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Multi-pass membrane protein.
Domain PF00027 Cyclic nucleotide-binding domain
Function

Visual signal transduction is mediated by a G-protein coupled cascade using cGMP as second messenger. This protein can be activated by cGMP which leads to an opening of the cation channel and thereby causing a depolarization of rod photoreceptors. Induced a flickering channel gating, weakened the outward rectification in the presence of extracellular calcium, increased sensitivity for L-cis diltiazem and enhanced the cAMP efficiency of the channel when coexpressed with CNGA3 (By similarity). Essential for the generation of light-evoked electrical responses in the red-, green- and blue sensitive cones.

> Gene Ontology
 
Biological Process GO:0006813 potassium ion transport
GO:0007601 visual perception
GO:0015672 monovalent inorganic cation transport
GO:0042391 regulation of membrane potential
GO:0050953 sensory perception of light stimulus
GO:0071804 cellular potassium ion transport
GO:0071805 potassium ion transmembrane transport
Molecular Function GO:0005216 ion channel activity
GO:0005217 intracellular ligand-gated ion channel activity
GO:0005221 intracellular cyclic nucleotide activated cation channel activity
GO:0005222 intracellular cAMP activated cation channel activity
GO:0005223 intracellular cGMP activated cation channel activity
GO:0005244 voltage-gated ion channel activity
GO:0005249 voltage-gated potassium channel activity
GO:0005261 cation channel activity
GO:0005267 potassium channel activity
GO:0015077 monovalent inorganic cation transmembrane transporter activity
GO:0015079 potassium ion transmembrane transporter activity
GO:0015267 channel activity
GO:0015276 ligand-gated ion channel activity
GO:0019001 guanyl nucleotide binding
GO:0022803 passive transmembrane transporter activity
GO:0022832 voltage-gated channel activity
GO:0022834 ligand-gated channel activity
GO:0022836 gated channel activity
GO:0022838 substrate-specific channel activity
GO:0022843 voltage-gated cation channel activity
GO:0030551 cyclic nucleotide binding
GO:0030553 cGMP binding
GO:0032561 guanyl ribonucleotide binding
GO:0043855 cyclic nucleotide-gated ion channel activity
GO:0046873 metal ion transmembrane transporter activity
Cellular Component GO:0001750 photoreceptor outer segment
GO:0005929 cilium
GO:0031513 nonmotile primary cilium
GO:0072372 primary cilium
GO:1902495 transmembrane transporter complex
GO:1990351 transporter complex
> KEGG and Reactome Pathway
 
KEGG hsa04024 cAMP signaling pathway
Reactome -
Summary
SymbolCNGB3
Namecyclic nucleotide gated channel beta 3
Aliases ACHM3; ACHM1; RMCH; achromatopsia (rod monochromacy) 3; achromatopsia (rod monochromacy) 1; CNG channel beta ......
Chromosomal Location8q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CNGB3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCNGB3
Namecyclic nucleotide gated channel beta 3
Aliases ACHM3; ACHM1; RMCH; achromatopsia (rod monochromacy) 3; achromatopsia (rod monochromacy) 1; CNG channel beta ......
Chromosomal Location8q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CNGB3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCNGB3
Namecyclic nucleotide gated channel beta 3
Aliases ACHM3; ACHM1; RMCH; achromatopsia (rod monochromacy) 3; achromatopsia (rod monochromacy) 1; CNG channel beta ......
Chromosomal Location8q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CNGB3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1350.798
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5960.604
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4480.746
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5950.0141
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CNGB3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.812.32.50.744
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.815.3-0.51
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211728.65.922.70.104
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131130.89.121.70.327
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolCNGB3
Namecyclic nucleotide gated channel beta 3
Aliases ACHM3; ACHM1; RMCH; achromatopsia (rod monochromacy) 3; achromatopsia (rod monochromacy) 1; CNG channel beta ......
Chromosomal Location8q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CNGB3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCNGB3
Namecyclic nucleotide gated channel beta 3
Aliases ACHM3; ACHM1; RMCH; achromatopsia (rod monochromacy) 3; achromatopsia (rod monochromacy) 1; CNG channel beta ......
Chromosomal Location8q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CNGB3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CNGB3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCNGB3
Namecyclic nucleotide gated channel beta 3
Aliases ACHM3; ACHM1; RMCH; achromatopsia (rod monochromacy) 3; achromatopsia (rod monochromacy) 1; CNG channel beta ......
Chromosomal Location8q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CNGB3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCNGB3
Namecyclic nucleotide gated channel beta 3
Aliases ACHM3; ACHM1; RMCH; achromatopsia (rod monochromacy) 3; achromatopsia (rod monochromacy) 1; CNG channel beta ......
Chromosomal Location8q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CNGB3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCNGB3
Namecyclic nucleotide gated channel beta 3
Aliases ACHM3; ACHM1; RMCH; achromatopsia (rod monochromacy) 3; achromatopsia (rod monochromacy) 1; CNG channel beta ......
Chromosomal Location8q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CNGB3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCNGB3
Namecyclic nucleotide gated channel beta 3
Aliases ACHM3; ACHM1; RMCH; achromatopsia (rod monochromacy) 3; achromatopsia (rod monochromacy) 1; CNG channel beta ......
Chromosomal Location8q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CNGB3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.